Full text is available at the source.
Abstract
Phase 2 clinical trials indicated promising signals for efficacy in glycemic control and weight management with daily injectable glucagon-like peptide-1 receptor agonists in type 1 diabetes.
- Larger phase 3 trials confirmed the efficacy of these drugs but identified safety concerns such as hypoglycemia and ketosis.
- Previous trials used a one-size-fits-all approach for insulin dosing without continuous glucose monitoring.
- Current focus has shifted to weekly injectable agents with a more personalized approach to insulin titration guided by continuous glucose monitoring.
Simplified